Literature DB >> 31837887

Association Between APOL1 Genotype and Need for Kidney Replacement Therapy in Patients Without Diabetes: Does Age Matter?

Jenny Wei1, Kirsten L Johansen2, Charles E McCulloch3, Michael Lipkowitz4, Matthew Weir5, Feng Lin3, Vito M Campese1, Miroslaw Smogorzewski1, Elaine Ku6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31837887      PMCID： PMC7652210          DOI： 10.1053/j.ajkd.2019.08.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  10 in total

1.  APOL1 risk variants, race, and progression of chronic kidney disease.

Authors:  Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

2.  Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.

Authors:  Elaine Ku; Michael S Lipkowitz; Lawrence J Appel; Afshin Parsa; Jennifer Gassman; David V Glidden; Miroslaw Smogorzewski; Chi-Yuan Hsu
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

3.  End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Authors:  Barry I Freedman; Carl D Langefeld; Kelly K Andringa; Jennifer A Croker; Adrienne H Williams; Neva E Garner; Daniel J Birmingham; Lee A Hebert; Pamela J Hicks; Mark S Segal; Jeffrey C Edberg; Elizabeth E Brown; Graciela S Alarcón; Karen H Costenbader; Mary E Comeau; Lindsey A Criswell; John B Harley; Judith A James; Diane L Kamen; S Sam Lim; Joan T Merrill; Kathy L Sivils; Timothy B Niewold; Neha M Patel; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Jane E Salmon; Betty P Tsao; Keisha L Gibson; Joyce R Byers; Anna K Vinnikova; Janice P Lea; Bruce A Julian; Robert P Kimberly
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

4.  Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.

Authors:  Teresa K Chen; Michael J Choi; W H Linda Kao; Brad C Astor; Julia J Scialla; Lawrence J Appel; Liang Li; Michael S Lipkowitz; Myles Wolf; Rulan S Parekh; Cheryl A Winkler; Michelle M Estrella; Deidra C Crews
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-01       Impact factor: 8.237

5.  Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.

Authors:  Raphaël Kormann; Anne-Sophie Jannot; Céline Narjoz; Jean-Antoine Ribeil; Sandra Manceau; Marianne Delville; Valentin Joste; Dominique Prié; Jacques Pouchot; Eric Thervet; Marie Courbebaisse; Jean-Benoît Arlet
Journal:  Br J Haematol       Date:  2017-07-12       Impact factor: 6.998

6.  Intensive blood-pressure control in hypertensive chronic kidney disease.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

7.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

Review 8.  Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.

Authors:  Barry I Freedman; Karl Skorecki
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 8.237

9.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

10.  APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.

Authors:  Shay Tzur; Saharon Rosset; Karl Skorecki; Walter G Wasser
Journal:  Nephrol Dial Transplant       Date:  2012-02-22       Impact factor: 5.992
  10 in total
  1 in total

1.  Race, APOL1 Risk Variants, and Clinical Outcomes among Older Adults: The ARIC Study.

Authors:  Teresa K Chen; Josef Coresh; Natalie Daya; Shoshana H Ballew; Adrienne Tin; Deidra C Crews; Morgan E Grams
Journal:  J Am Geriatr Soc       Date:  2020-09-07       Impact factor: 5.562
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.